Analysts’ Weekly Ratings Changes for GRAIL (GRAL)

GRAIL (NASDAQ: GRAL) has recently received a number of price target changes and ratings updates:

• 10/13/2026 – GRAIL had its price target raised by TD Cowen from $88.00 to $180.00. They now have a “buy” rating on the stock.
• 10/12/2026 – GRAIL had its price target raised by Morgan Stanley from $60.00 to $120.00. They now have an “equal weight” rating on the stock.
• 10/2/2026 – GRAIL had its price target raised by UBS Group AG from $105.00 to $175.00. They now have a “buy” rating on the stock.
• 10/1/2026 – GRAIL had its price target raised by Guggenheim from $75.00 to $155.00. They now have a “buy” rating on the stock.
• 9/28/2026 – GRAIL had its price target raised by Canaccord Genuity Group Inc. from $80.00 to $150.00. They now have a “buy” rating on the stock.
• 9/25/2026 – GRAIL had its price target raised by Mizuho from $65.00 to $100.00. They now have a “neutral” rating on the stock.
• 9/24/2026 – GRAIL had its “buy” rating reaffirmed by TD Cowen.
• 9/22/2026 – GRAIL had its price target raised by Robert W. Baird from $96.00 to $118.00. They now have an “outperform” rating on the stock.
• 9/17/2026 – GRAIL was given a new $84.00 price target by UBS Group AG.
• 9/17/2026 – GRAIL is now covered by Royal Bank Of Canada. They set a “sector perform” rating and a $84.00 price target on the stock.
• 9/17/2026 – GRAIL is now covered by Royal Bank Of Canada. They set a “hold” rating and a $84.00 price target on the stock.
• 9/13/2026 – GRAIL was upgraded by Wall Street Zen from “sell” to “hold”.
• 9/9/2026 – GRAIL is now covered by UBS Group AG. They set a “buy” rating and a $105.00 price target on the stock.
• 9/9/2026 – GRAIL is now covered by UBS Group AG. They set a “buy” rating and a $105.00 price target on the stock.
• 9/5/2026 – GRAIL was downgraded by Wall Street Zen from “hold” to “sell”.

Insider Transactions at GRAIL

In related news, insider Andrew Partridge sold 7,873 shares of GRAIL stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $146.39, for a total transaction of $1,152,528.47. Following the completion of the transaction, the insider directly owned 155,865 shares in the company, valued at $22,817,077.35. The trade was a 4.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Aaron Freidin sold 23,619 shares of the company’s stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $146.39, for a total value of $3,457,585.41. Following the completion of the sale, the chief financial officer directly owned 225,364 shares in the company, valued at approximately $32,991,035.96. The trade was a 9.49% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 109,944 shares of company stock valued at $12,095,805 in the last ninety days. Corporate insiders own 1.83% of the company’s stock.

GRAIL, Inc is a healthcare company focused on developing blood-based technologies for the early detection of cancer. Its goal is to identify cancer signals before symptoms appear, when treatment may be more effective, by applying genomics, machine learning and other analytical methods to blood samples.

The company’s primary product is the Galleri multi-cancer early detection test, a prescription laboratory-developed test designed to screen for signals associated with multiple types of cancer from a single blood draw.